Becton, Dickinson and Company (NYSE:BDX) (NYSE: BDX), commonly known as BD, is a leading global medical technology firm that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. Its products support healthcare providers in areas such as medication management, infection prevention, diabetes care, oncology, and surgery. Key offerings include syringes and needles, infusion therapy systems, diagnostic products for microbiology and molecular testing, flow cytometry instruments, and vascular access devices.
Founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, the company has grown through strategic acquisitions and innovation. Notable transactions include the acquisition of C. R. Bard in 2017, which expanded BD’s portfolio of vascular, urology and oncology products. Over more than a century, BD has invested in research and development to drive advances in safety-engineered devices and life sciences research tools.
BD operates across three principal segments: BD Medical, BD Life Sciences and BD Interventional. Its global footprint extends to more than 190 countries, with major manufacturing and research facilities in North America, Europe, Asia and Latin America. The company serves hospitals, pharmaceutical firms, clinical laboratories, academic research centers and home healthcare markets, emphasizing product quality, regulatory compliance and patient safety.
Headquartered in Franklin Lakes, New Jersey, BD is led by President and Chief Executive Officer Thomas “Tom” Polen, who has guided the company’s strategic growth since 2020. Under his leadership, BD continues to pursue digital health initiatives, expand its biologics capabilities and strengthen its commitment to reducing the spread of infectious disease worldwide.
